

Accepted Manuscript

Title: Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis

Authors: Fan Feng, Qiyu Jiang, Hui Jia, Huiwei Sun, Yantao Chai, Xiaojuan Li, Guanghua Rong, Yingshi Zhang, Zhengping Li



PII: S1043-6618(18)30769-2
DOI: <https://doi.org/10.1016/j.phrs.2018.06.021>
Reference: YPHRS 3928

To appear in: *Pharmacological Research*

Received date: 30-5-2018

Revised date: 13-6-2018

Accepted date: 20-6-2018

Please cite this article as: Feng F, Jiang Q, Jia H, Sun H, Chai Y, Li X, Rong G, Zhang Y, Li Z, Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis, *Pharmacological Research* (2018), <https://doi.org/10.1016/j.phrs.2018.06.021>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis

Fan Feng^a, Qiyu Jiang^b, Hui Jia^c, Huiwei Sun^b, Yantao Chai^b, Xiaojuan Li^b, Guanghua Rong^{c,*}, Yingshi Zhang^{d,*}, Zhengping Li^{a,**}

^aSchool of Chemistry and Biological Engineering, University of Science and Technology Beijing Beijing, 100083, P. R. China;

^bResearch Center for Clinical and Translational Medicine, The 302nd Hospital of Chinese PLA, Beijing 100039, P.R. China;

^cThe Comprehensive Liver Cancer Center, Beijing 302 Hospital, Beijing 100039, P.R. China;

^dDepartment of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, P.R. China.

****Corresponding to Prof. Zhengping Li, School of Chemistry and Biological Engineering, University of Science and Technology Beijing, No. 30 Xueyuan Road, Haidian District, Beijing 100083, P. R. China; TEL./FAX.: +86-10-62333165; Email: lzpbd@ustb.edu.cn;**

***Corresponding to Dr. Yingshi Zhang, Department of Clinical Pharmacy, Shenyang Pharmaceutical University, No.103 Wenhua Road, Shenhe District, Shenyang 110016, P. R. China; Email: zhangyingshi526@163.com.**

***Corresponding to Dr. Guanghua Rong, The Comprehensive Liver Cancer Center, Beijing 302 Hospital, Beijing 100039, P.R. China; Email: shengfandayeren@126.com.**

Download English Version:

<https://daneshyari.com/en/article/8536083>

Download Persian Version:

<https://daneshyari.com/article/8536083>

[Daneshyari.com](https://daneshyari.com)